Yamane T, Inoue T, Furukawa Y, Sasaki A, Kishida T, Park K, Im T, Tatsumi N
Osaka City University Medical School, Dept. of Laboratory Medicine.
Gan To Kagaku Ryoho. 1989 Dec;16(12):3729-33.
Eleven patients with acute leukemia were treated with MB-triple V therapy consisting of mitoxantrone, behenoyl-arabinoside, etoposide, vincristine and vindesine. In this regimen, the target points were set for WBC count in the peripheral blood (less than 1,500/microliters) and TNC count in the bone marrow (less than 15,000/microliters). In this study, we compared the WBC count in nadir state and the duration until WBC count returned to above 1,000/microliters between 11 patients with MB-triple V therapy and 15 patients with B-triple V therapy in which target points were not set. In particular, the standard distribution of WBC count in nadir state of MB-triple V group was significantly smaller than that of B-triple V group. The number of early deaths in the course of MB-triple V (0/11, 0%) decreased compared with B-triple V group (3/15, 20%). Seven patients of the eleven patients with this regimen achieved CR state (63.6%). Hereafter, further cases are necessary before this combination chemotherapy as a part of the induction therapy is evaluated.
11例急性白血病患者接受了由米托蒽醌、山嵛酰阿糖胞苷、依托泊苷、长春新碱和长春地辛组成的MB三联V疗法。在该方案中，设定外周血白细胞计数（低于1500/微升）和骨髓有核细胞计数（低于15000/微升）的目标值。在本研究中，我们比较了11例接受MB三联V疗法的患者与15例未设定目标值的接受B三联V疗法的患者在最低点状态下的白细胞计数以及白细胞计数恢复到1000/微升以上所需的持续时间。特别是，MB三联V组最低点状态下白细胞计数的标准分布明显小于B三联V组。MB三联V治疗过程中的早期死亡人数（0/11，0%）与B三联V组（3/15，20%）相比有所减少。接受该方案的11例患者中有7例达到完全缓解状态（63.6%）。此后，在评估这种联合化疗作为诱导治疗一部分之前，还需要更多病例。
